How We Drove 39% Monthly New Patient Growth for FC2, Cutting CPA 24% in 60 Days
Intro
FC2 is the only FDA-approved internal (female) condom available in the U.S., dispensed by prescription and shipped directly to patients. Their business depends on one thing: getting more women through a telehealth flow to request the Rx. That made this account doubly hard. We're advertising a prescription product in a sensitive women's health category — which means elevated CPCs, frequent ad rejections, a mandatory MLR (medical/legal review) cycle on every asset, and a target audience that the Meta algorithm doesn't reflexively know how to find.
When we took over, the account was running multiple optimization events in parallel, spend was fragmented across too many campaigns, and the audience was wide enough that a meaningful share of clicks were coming from men who would never convert. In 60 days, we rebuilt the structure, narrowed the audience, and stood up a creative engine that could keep pace with Meta's rejection rate — driving 39% monthly patient growth at a 24% lower CPA.
Ad Account Structure and Scaling
The first move was simplification. The account was running both Purchase and "Interested" (lead) optimization campaigns simultaneously, which sounds reasonable but in practice fragments the signal Meta uses to find your buyer. CPA was volatile, and every scale-up was getting reset by an underperforming Purchase campaign reshuffling distribution. We killed every Purchase campaign and went all-in on Interested as the single conversion event. Within a couple of weeks the in-platform CPA stabilized and we had a clean baseline to scale against.
From there we rebuilt the structure around three workloads: a Challengers ASC as the scale workhorse, an Audience Testing CBO to layer in incremental signal from broad and interest-based audiences, and a dedicated Creative Testing campaign for new concepts. We moved creative testing out of a traditional CBO and into an ASC, because FC2's CPA sits higher than a typical ecom baseline — and ASC gave Meta the room to find pockets of demand a fragmented adset structure couldn't.
The audience work mattered as much as the structure. Early data showed the Challengers ASC was pushing 68% of its clicks to men at a $0.17 CPC — beautiful soft metrics, zero conversion lift. We rebuilt the audience to exclude men entirely. A few weeks later, the 65+ age cohort showed the same pattern: very cheap clicks, no conversions. We cut it. We landed on women, 21–64, with the algorithm naturally allocating the majority of spend to the 35+ range — which matched the demographic the product was clinically built for.
Once the structure stabilized, we scaled spend in 10–20% increments every few days, holding the line on CPA. We made it a rule to leave the account alone on weekends when Meta's data is noisier, and resisted the temptation to react to any single soft day. Meta is a machine learning model, and models reward stability.
Creative Strategy
In a pharma-adjacent category, your creative pipeline is your moat. Meta flags Rx ads constantly, and an account that can't replace a paused winner inside 48 hours loses spend. We built one with that constraint baked in.
Our creator roster was assembled deliberately around the target demographic. An early test with creators in the 18–30 age range produced CPCs roughly 2x our baseline, confirming we were talking to the wrong audience — so we onboarded UGC partners (Paige, Sophia, Angela, Jillian, Lila V) who matched the ~40-year-old demographic the product is built for. Every creator shoot turned into multiple asset types: standalone UGC videos, Flighted-edited recuts, UGC mashups remixing top-performing audio with new b-roll, and slideshow formats for placement diversity.
Beyond format diversity, we leaned hard into persona and angle testing. Rather than running one generic value prop, we built creative around discrete personas (perimenopause, latex allergy) and angles ("$0 with insurance," "may cover more surface area than male condoms for STI prevention," "feels better than male condoms"). That gave Meta multiple qualified hooks to find the right patient, and gave us a deeper bench of winners as individual ads inevitably fatigued or got flagged.
The top breakouts — "Watch This Hack," the "UGC Value Props + Ad Comments" mashup, the "How It Works – Curiosity Angle" video — all followed the same pattern: launch in Creative Testing, scale into Challengers once efficiency held, then iterate aggressively. We also pulled organic content directly off FC2's Instagram and boosted top-performing IG Reels as ads in an Upper Funnel campaign, which consistently outperformed the same content uploaded as a standard ad.
Conclusion
A simpler structure, a cleaner audience, and a creative engine built for a high-rejection-risk category — that's the formula behind 39% monthly patient growth and a 24% CPA reduction in 60 days. FC2's Meta program is now built to scale: a single optimization event the algorithm can lock onto, an audience filtered down to the women the product actually serves, and a creative pipeline that can keep producing winners faster than Meta can reject them.
